Pharmafile Logo
Pharmafocus logo
Advanced Search

BMS

Showing 15 posts of 286 posts found.

NICE won’t approve Abilify without more data

September 13, 2010
Sales and Marketing Abilify, BMS, NICE

NICE is unlikely to approve Bristol-Myers Squibb’s schizophrenia drug Abilify unless the company can provide more data on its clinical …

News
Patrick_Hopkinson

BMS appoints UK market access director

September 13, 2010
Sales and Marketing BMS, UK, appointment, sales and marketing

Patrick Hopkinson has joined Bristol-Myers Squibb as director of market access and external affairs in the UK. He joins the …

Appointment
Andreotti

BMS to acquire ZymoGenetics

September 8, 2010
Research and Development, Sales and Marketing BMS, hepatitis

 Bristol-Myers Squibb is to acquire biopharma company ZymoGenetics for $885 million to add to its ‘string of pearls’of small biotech …

News
melanoma

BMS’ melanoma drug given priority review

August 19, 2010
Sales and Marketing BMS, ipilimumab

Bristol-Myers Squibb’s promising new treatment for skin cancer melanoma has been given a priority review by the FDA. The company …

News

Excipient problem leads to Coumadin recall

July 20, 2010
Manufacturing and Production BMS, manufacturing compliance, recalls

Bristol-Myers Squibb is recalling nearly 150,000 tablets of its anticoagulant product Coumadin distributed across the US because some of them …

News

Pharma manufacturing news in brief

July 6, 2010
Manufacturing and Production BMS, Borregaard Synthesis, Colorcon, JHP Pharma, Saltigo, Sanofi-Aventis, Synthetech, Viropharma, univar

New capital investments from Sanofi-Aventis, Bristol-Myers Squibb, Viropharma and Colorcon head up this round-up of developments in the pharmaceutical manufacturing …

News

BMS factory closure could interrupt HIV drug supply

June 11, 2010
Manufacturing and Production BMS, HIV, manufacturing, supply chain

Closure of a manufacturing facility in France operated by Bristol-Myers Squibb could lead to shortages of an important treatment for …

News

BMS on tenterhooks over belatacept future

May 4, 2010
Research and Development BMS, belatacept

Bristol-Myers Squibb has been kept on tenterhooks by US regulator the FDA over the future of its investigational kidney transplant …

News

Plavix boosts BMS first quarter figures

April 30, 2010
Sales and Marketing BMS, Plavix

Plavix has boosted Bristol-Myers Squibb’s performance in the first quarter of the year, with sales of the anti-clotting blockbuster up …

News
Blood clot

Phase III success for apixaban

March 5, 2010
Research and Development BMS, Pfizer, VTE, apixaban

Pfizer and Bristol-Myers Squibb’s apixaban has shown promising results in a late-stage head-to-head trial with Sanofi-Aventis’ Lovenox. The oral anti-coagulant …

News
Andreotti

Lamberto Andreotti new head of Bristol-Myers Squibb

March 4, 2010
Research and Development, Sales and Marketing BMS, appointment, research and development, sales and marketing

Bristol-Myers Squibb has appointed Lamberto Andreotti its new chief executive with effect from 4 May, succeeding James Cornelius who will …

Appointment

NICE warns industry on cost-effectiveness

February 9, 2010
Sales and Marketing BMS, Janssen, NICE, Novartis, hta

NICE has turned down three drugs on cost grounds and has urged the pharma industry to do more to help …

News

BMS profits buoyant after Mead Johnson jettisoned

February 1, 2010
Sales and Marketing 2009 financials, BMS, Mead Johnson

Bristol-Myers Squibb’s have revealed continued strong sales of the anti-blood clotting treatment Plavix and the antipsychotic Abilify and a huge …

News
Orencia

Orencia wins expanded European licence

January 27, 2010
Sales and Marketing BMS, Orencia, rheumatoid arthritis

BMS’s Orencia has been approved in Europe to treat children aged six and over who suffer from a form of …

News
charles_bancroft_casual

Bristol-Myers Squibb appoints Charles Bancroft acting chief financial officer

January 15, 2010
Sales and Marketing BMS, appointment, sales and marketing

Charles Bancroft has been appointed acting chief financial officer at Bristol-Myers Squibb, replacing Jean-Marc Huet who left the company at …

Appointment
The Gateway to Local Adoption Series

Latest content

Teva announces positive results from trial of AJOVY for migraine

December 5, 2025

Vetter announces leadership transition as Thomas Otto retires

December 5, 2025

Samsung Bioepis announces launch of two new denosumab biosimilars in Europe

December 4, 2025

Medicus Pharma appoints Carolyn Bonner as CFO

December 4, 2025

Sandoz launches two new bone disease biosimilars in Europe

December 3, 2025